FY2025 · period end Dec '25 · from the 10-K filed Mar 24, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | negative: -$0.05B | negative: -$0.04B | negative: -$0.03B | negative: -$0.04B | negative: -$0.03B |
| EPS (Diluted) | negative: -$1.25 | negative: -$1.24 | negative: -$1.50 | negative: -$4.00 | negative: -$4.08 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.04B | $0.04B | $0.02B | $0.03B | $0.05B |
| Total Liabilities | $0.02B | $0.02B | $0.02B | $0.02B | $0.02B |
| Stockholders' Equity | $0.02B | $0.02B | negative: -$0.00B | $0.01B | $0.03B |
| Cash & Equivalents | $0.02B | $0.01B | $0.02B | $0.02B | $0.04B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.05B | negative: -$0.03B | negative: -$0.02B | negative: -$0.04B | negative: -$0.03B |
| Capital Expenditures | $0.00B | — | $0.00B | — | — |
| Free Cash Flow | negative: -$0.05B | — | negative: -$0.02B | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Margin | — | — | — | — | — |
| Return on Equity | negative: -254.0% | negative: -190.6% | 2059.0% | negative: -510.1% | negative: -118.2% |
| Return on Assets | negative: -130.8% | negative: -103.1% | negative: -153.9% | negative: -141.3% | negative: -69.8% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
Who is buying and selling ACHIEVE LIFE SCIENCES, INC. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on ACHV yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on ACHV and publish the result to your public profile.
Ask about ACHIEVE LIFE SCIENCES, INC.
Continue in Workspace — cited answers on ACHV, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs